Selective inhibitors of COX-2

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) primarily target prostaglandin G/H synthase (PGHS), also known as cyclooxygenase (COX).
• PGHS exists in two main isoforms, PGHS-1 and PGHS-2, with distinct physiological and pathological roles.
• Understanding the differential contributions and drug sensitivities of these isoforms is crucial for developing targeted anti-inflammatory therapies.

Purpose of the Study:

• To establish high-level expression systems for recombinant human PGHS isoforms.
• To characterize the inducible PGHS-2 isoform in detail.
• To evaluate the sensitivity and selectivity of various NSAIDs, including novel compounds, against both PGHS isoforms.

Main Methods:

• Development of high-level expression systems for recombinant human PGHS-1 and PGHS-2.
• Purification and comprehensive characterization of recombinant PGHS-2.
• Enzymatic assays and pharmacological profiling of recombinant PGHS isoforms with different NSAIDs.

Main Results:

• Recombinant PGHS-2 was successfully purified and characterized for enzymatic activity, substrate specificity, and structural properties.
• Conventional NSAIDs demonstrated limited selectivity between PGHS-1 and PGHS-2.
• The NSAID NS-398 exhibited significant time-dependent specificity for inhibiting PGHS-2.

Conclusions:

• The established expression systems enable detailed study of PGHS isoform function and inhibition.
• Conventional NSAIDs lack isoform selectivity, potentially contributing to side effects.
• NS-398 represents a promising NSAID candidate with high PGHS-2 specificity, suggesting potential for targeted anti-inflammatory action.